DBV TECHNOLOGIES SA revenue breakdown overview

DBV TECHNOLOGIES SA revenue for the last year amounted to 14.35 M EUR, the most of which — 14.55 M EUR — came from its highest performing source at the moment, Epicutaneous Immunotherapy Products, the year earlier bringing 4.61 M EUR. The greatest contribution to the revenue figure was made by France — last year it brought DBV TECHNOLOGIES SA 14.55 M EUR, and the year before that — 4.61 M EUR.